<?xml version="1.0" encoding="UTF-8"?>
<ref id="R40">
 <label>40</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name name-style="western">
    <surname>Gardiner</surname>
    <given-names>D</given-names>
   </name>, 
   <name name-style="western">
    <surname>Lalezari</surname>
    <given-names>J</given-names>
   </name>, 
   <name name-style="western">
    <surname>Lawitz</surname>
    <given-names>E</given-names>
   </name>, 
   <etal>et al</etal>
  </person-group>
  <article-title>A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection</article-title>. 
  <source>PLoS One</source>
  <year>2013</year>;
  <volume>8</volume>:
  <elocation-id>e63818</elocation-id>. 
  <pub-id pub-id-type="doi">10.1371/journal.pone.0063818</pub-id>
  <?supplied-pmid http://www.ncbi.nlm.nih.gov/pubmed/23717490?>
  <pub-id pub-id-type="pmid">23717490</pub-id>
 </mixed-citation>
</ref>
